Phase 1/2 trial of TAME(:Transcatheter arterial micro embolization) for chronic musculoskeletal pain refractory to non-surgical management

Phase 1/2 trial of TAME(:Transcatheter arterial micro embolization) for chronic musculoskeletal pain refractory to non-surgical management - TAME Phase 1/2 study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014591

Enrollment

Registered

2014-07-20

Start date

2014-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal chronic pain refractory to non-surgical management

Interventions

Transcatheter arterial micro-embolization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Previous conservative therapies applied for at least 3 months and persistent moderate-to-severe pain (VAS > 50mm). 2.Patients with following diagnosis: adhesive capsulitis, musculoskeletal shoulder pain, tendinopathy and enthesopathy, sinovitis and bursitis, mild osteoarthritis (KL<3), infrapatellar fat pad inflammation, and residual or reccurent pain after knee replacement surgery. 3. Patients who maintain major organ (bone marrow, heart, liver, lung, kidney) function. 4. Provided written informed consent to undergo the procedure.

Exclusion criteria

Exclusion criteria: 1.Reheumatoid arthritis 2.Neoplasm 3.Severe arteriosclerosis 4.Pregnant female 5.Dementia 6.Complaining joint instability 7.Iodine Allergy 8.Patients with severe cardiac disease, cerebrovascular disease, neurological disease, uncontrollable diabetic mellitus and hypertension, severe infection, intestinal bleeding, interstitial pneumonia, ascites fluid, pleural effusion. 9, Pain due to cervical or lumbar spine pathology 10,Patients who was decided not to be appropriate for this trial by physician

Design outcomes

Primary

Measure	Time frame
Feasibility	—

Secondary

Measure	Time frame
Effectiveness Frequency of adverse events	—

Countries

Japan

Contacts

Public ContactYuji Okuno

secretariat of Edogawa Musculoskeletal Intervention Study Group Orthopedic Surgery

how_lowlow@yahoo.co.jp03-3673-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026